Literature DB >> 31990315

Yield of a Public Health Screening of Children for Islet Autoantibodies in Bavaria, Germany.

Anette-Gabriele Ziegler1,2,3, Kerstin Kick1,3, Ezio Bonifacio4,5,6, Florian Haupt1,3, Markus Hippich1,3, Desiree Dunstheimer7, Martin Lang8, Otto Laub9, Katharina Warncke10, Karin Lange11, Robin Assfalg1,3, Manja Jolink1,3, Christiane Winkler1,3, Peter Achenbach1,2,3.   

Abstract

IMPORTANCE: Public health screening for type 1 diabetes in its presymptomatic stages may reduce disease severity and burden on a population level.
OBJECTIVE: To determine the prevalence of presymptomatic type 1 diabetes in children participating in a public health screening program for islet autoantibodies and the risk for progression to clinical diabetes. DESIGN, SETTING, AND PARTICIPANTS: Screening for islet autoantibodies was offered to children aged 1.75 to 5.99 years in Bavaria, Germany, between 2015 and 2019 by primary care pediatricians during well-baby visits. Families of children with multiple islet autoantibodies (presymptomatic type 1 diabetes) were invited to participate in a program of diabetes education, metabolic staging, assessment of psychological stress associated with diagnosis, and prospective follow-up for progression to clinical diabetes until July 31, 2019. EXPOSURES: Measurement of islet autoantibodies. MAIN OUTCOMES AND MEASURES: The primary outcome was presymptomatic type 1 diabetes, defined by 2 or more islet autoantibodies, with categorization into stages 1 (normoglycemia), 2 (dysglycemia), or 3 (clinical) type 1 diabetes. Secondary outcomes were the frequency of diabetic ketoacidosis and parental psychological stress, assessed by the Patient Health Questionnaire-9 (range, 0-27; higher scores indicate worse depression; ≤4 indicates no to minimal depression; >20 indicates severe depression).
RESULTS: Of 90 632 children screened (median [interquartile range {IQR}] age, 3.1 [2.1-4.2] years; 48.5% girls), 280 (0.31%; 95% CI, 0.27-0.35) had presymptomatic type 1 diabetes, including 196 (0.22%) with stage 1, 17 (0.02%) with stage 2, 26 (0.03%) with stage 3, and 41 who were not staged. After a median (IQR) follow-up of 2.4 (1.0-3.2) years, another 36 children developed stage 3 type 1 diabetes. The 3-year cumulative risk for stage 3 type 1 diabetes in the 280 children with presymptomatic type 1 diabetes was 24.9% ([95% CI, 18.5%-30.7%]; 54 cases; annualized rate, 9.0%). Two children had diabetic ketoacidosis. Median (IQR) psychological stress scores were significantly increased at the time of metabolic staging in mothers of children with presymptomatic type 1 diabetes (3 [1-7]) compared with mothers of children without islet autoantibodies (2 [1-4]) (P = .002), but declined after 12 months of follow-up (2 [0-4]) (P < .001). CONCLUSIONS AND RELEVANCE: Among children aged 2 to 5 years in Bavaria, Germany, a program of primary care-based screening showed an islet autoantibody prevalence of 0.31%. These findings may inform considerations of population-based screening of children for islet autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31990315      PMCID: PMC6990943          DOI: 10.1001/jama.2019.21565

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  38 in total

1.  An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.

Authors:  Kevan C Herold; Brian N Bundy; S Alice Long; Jeffrey A Bluestone; Linda A DiMeglio; Matthew J Dufort; Stephen E Gitelman; Peter A Gottlieb; Jeffrey P Krischer; Peter S Linsley; Jennifer B Marks; Wayne Moore; Antoinette Moran; Henry Rodriguez; William E Russell; Desmond Schatz; Jay S Skyler; Eva Tsalikian; Diane K Wherrett; Anette-Gabriele Ziegler; Carla J Greenbaum
Journal:  N Engl J Med       Date:  2019-06-09       Impact factor: 91.245

2.  Prediction of type 1 diabetes in Sardinian schoolchildren using islet cell autoantibodies: 10-year follow-up of the Sardinian schoolchildren type 1 diabetes prediction study.

Authors:  Fernanda Velluzzi; Gianni Secci; Vincenzo Sepe; Catherine Klersy; Marion Shattock; Richard Foxon; Marco Songini; Stefano Mariotti; Mattia Locatelli; Gian Franco Bottazzo; Andrea Loviselli
Journal:  Acta Diabetol       Date:  2015-04-22       Impact factor: 4.280

3.  Karlsburg Type I diabetes risk study of a general population: frequencies and interactions of the four major Type I diabetes-associated autoantibodies studied in 9419 schoolchildren.

Authors:  M Strebelow; M Schlosser; B Ziegler; I Rjasanowski; M Ziegler
Journal:  Diabetologia       Date:  1999-06       Impact factor: 10.122

Review 4.  Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression.

Authors:  Johann Große; Henriette Hornstein; Ulf Manuwald; Joachim Kugler; Ingmar Glauche; Ulrike Rothe
Journal:  Horm Metab Res       Date:  2018-03-09       Impact factor: 2.936

Review 5.  General population screening for type 1 diabetes: has its time come?

Authors:  Richard A Insel; Jessica L Dunne; Anette-G Ziegler
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-08       Impact factor: 3.243

6.  Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance.

Authors:  Kazuhiko Sakaguchi; Kazuo Takeda; Mitsuo Maeda; Wataru Ogawa; Toshiyuki Sato; Seiki Okada; Yasuhito Ohnishi; Hiromu Nakajima; Atsunori Kashiwagi
Journal:  Diabetol Int       Date:  2015-05-14

Review 7.  Type 1 diabetes.

Authors:  Mark A Atkinson; George S Eisenbarth; Aaron W Michels
Journal:  Lancet       Date:  2013-07-26       Impact factor: 79.321

8.  Does diabetes appear in distinct phenotypes in young people? Results of the diabetes mellitus incidence Cohort Registry (DiMelli).

Authors:  Katharina Warncke; Miriam Krasmann; Ramona Puff; Desirée Dunstheimer; Anette-Gabriele Ziegler; Andreas Beyerlein
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

9.  Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children.

Authors:  Fergus J Cameron; Shannon E Scratch; Caroline Nadebaum; Elisabeth A Northam; Ildiko Koves; Juliet Jennings; Kristina Finney; Jeffrey J Neil; R Mark Wellard; Mark Mackay; Terrie E Inder
Journal:  Diabetes Care       Date:  2014-06       Impact factor: 19.112

10.  Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association.

Authors:  Jane L Chiang; David M Maahs; Katharine C Garvey; Korey K Hood; Lori M Laffel; Stuart A Weinzimer; Joseph I Wolfsdorf; Desmond Schatz
Journal:  Diabetes Care       Date:  2018-08-09       Impact factor: 19.112

View more
  36 in total

1.  Simulating Screening for Risk of Childhood Diabetes: The Collaborative Open Outcomes tooL (COOL).

Authors:  Mohamed Ghalwash; Eileen Koski; Riitta Veijola; Jorma Toppari; William Hagopian; Marian Rewers; Vibha Anand
Journal:  AMIA Annu Symp Proc       Date:  2022-02-21

Review 2.  Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies.

Authors:  Stephen R Karpen; Jessica L Dunne; Brigitte I Frohnert; Marjana Marinac; Claudia Richard; Sarah E David; Inish M O'Doherty
Journal:  Diabetologia       Date:  2022-07-22       Impact factor: 10.460

3.  Quantifying the utility of islet autoantibody levels in the prediction of type 1 diabetes in children.

Authors:  Kenney Ng; Vibha Anand; Harry Stavropoulos; Riitta Veijola; Jorma Toppari; Marlena Maziarz; Markus Lundgren; Kathy Waugh; Brigitte I Frohnert; Frank Martin; Olivia Lou; William Hagopian; Peter Achenbach
Journal:  Diabetologia       Date:  2022-10-05       Impact factor: 10.460

4.  Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening.

Authors:  Andreas Weiss; Jose Zapardiel-Gonzalo; Franziska Voss; Manja Jolink; Joanna Stock; Florian Haupt; Kerstin Kick; Tiziana Welzhofer; Anja Heublein; Christiane Winkler; Peter Achenbach; Anette-Gabriele Ziegler; Ezio Bonifacio
Journal:  Diabetologia       Date:  2022-08-27       Impact factor: 10.460

Review 5.  100 years of insulin: celebrating the past, present and future of diabetes therapy.

Authors:  Emily K Sims; Alice L J Carr; Richard A Oram; Linda A DiMeglio; Carmella Evans-Molina
Journal:  Nat Med       Date:  2021-07-15       Impact factor: 53.440

6.  Characterising the age-dependent effects of risk factors on type 1 diabetes progression.

Authors:  Michelle So; Colin O'Rourke; Alyssa Ylescupidez; Henry T Bahnson; Andrea K Steck; John M Wentworth; Brittany S Bruggeman; Sandra Lord; Carla J Greenbaum; Cate Speake
Journal:  Diabetologia       Date:  2022-01-18       Impact factor: 10.122

7.  Detecting insulitis in type 1 diabetes with ultrasound phase-change contrast agents.

Authors:  David G Ramirez; Mark Ciccaglione; Awaneesh K Upadhyay; Vinh T Pham; Mark A Borden; Richard K P Benninger
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-12       Impact factor: 11.205

8.  An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood.

Authors:  Ezio Bonifacio; Andreas Weiß; Christiane Winkler; Markus Hippich; Marian J Rewers; Jorma Toppari; Åke Lernmark; Jin-Xiong She; William A Hagopian; Jeffrey P Krischer; Kendra Vehik; Desmond A Schatz; Beena Akolkar; Anette-Gabriele Ziegler
Journal:  Diabetes Care       Date:  2021-02-24       Impact factor: 17.152

9.  One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.

Authors:  Kimber M Simmons; Jay M Sosenko; Megan Warnock; Susan Geyer; Heba M Ismail; Helena Elding Larsson; Andrea K Steck
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

10.  Diabetic Ketoacidosis at Manifestation of Type 1 Diabetes in Childhood and Adolescence—Incidence and Risk Factors.

Authors:  Hugo Segerer; Michael Wurm; Julia M Grimsmann; Beate Karges; Andreas Neu; Marina Sindichakis; Katharina Warncke; Axel Dost; Reinhard W Holl
Journal:  Dtsch Arztebl Int       Date:  2021-06-04       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.